Prevention of Thromboembolism with Low-Molecular-Weight Heparin in Orthopedic Surgery: A 5-Year Experience

Abstract

A regimen of prophylaxis of thromboembolism with low molecular weight heparin (LMWH) and unfractionated heparin (UFH) in orthopedic surgery is presented. Over a 5-year period, 11,905 patients have been operated in all fields of orthopedic surgery in a big trauma center. In 498 cases, deep vein thrombosis (DVT) was clinically suspected and phlebography was performed: 122 patients had confirmed DVT (rate 0.98%); 59.8% of the DVT were limited to the calf. Nineteen pulmonary embolisms (rate 0.16%) were diagnosed (3 lethal). Heparin-induced thrombocytopenia type II was diagnosed in 12 of 122 patients. Only one of these had received LMWH. The related rates of DVT were highest for tibial head fractures (12.4%), total knee replacement (6.7%), and multiple trauma (6.4%). The extent of DVT was most severe in multiple trauma. The results proved the regimen to be of good clinical use and showed that more attention has to be paid to fractures, especially of the knee; and to patients with multiple injuries.

Keywords

Prevention of thromboembolism Unfractionated heparin Low-molecular-weight heparin Heparin-induced thrombocytopenia Diagnosis-related incidences of DVT

References

1. Turpie AG , Eriksson BI , Lassen MR , et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery. J South Orthop Assoc 2002; 11: 182-182.

2. Kemkes-Matthes B . Hirudin for prophylaxis and treatment of deep vein thrombosis. Semin Thromb Hemost 2002; 28:455-455.

3. Eriksson BI , Agnelli G , Cohen AT , et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-288.

4. Haas S , Haas P . The efficacy of low molecular weight heparins-an overview. Semin Thromb Hemost 1993;19 (Suppl 1):101-101.

5. Leizorovicz A , Haugh MC , Chapuis FR , et al. Low molecular weight heparin in the prevention of perioperative thrombosis. BMJ 1992;305:913-913.

6. Nurmohamed MT , Rosendal FR , Biller HR , et al. Lowmolecular-weight heparin versus standard heparin in general and orthopedic surgery: A meta-analysis. Lancet 1992;340: 152-152.

7. Hull RD , Pineo GF , Francis C , et al. Low-molecular-heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients. Arch Intern Med 2000;1600:2199-2199.

8. Planes A , Samama MM , Lensing AW , Buller HR , et al. Prevention of deep vein thrombosis after hip replacementcomparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81(1):22-22.

9. Guidelines for prevention thromboembolism in surgery. German Society of Surgery, 2000

10.

10. Nicolaides AN , Arcelus J , Belcaro G , et al. Prevention of venous thromboembolism. European Consensus Statement. Int Angiol 1992;11:151-151.

11.

11. Blanchard J , Meuwly JY , Leyvraz PF , et al. Prevention of deep vein thrombosis after total knee replacement. J Bone Joint Surg 1999;81:654-654.

12.

12. Eriksson BI , Kalebo P , Anthymr BA , et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg 1991;73:484-484.

13.

13. Warkentin TE , Levine MN , Hirsh J , et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-1330.